Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Pepkon logo — Pioneering breakthrough peptides for treating challenging ca...

Pepkon

Pioneering breakthrough peptides for treating challenging cancers with precision and hope.

Founded 2022 France France 10 employees Non Equity Assistance Biotechnology

General Information

Company Name Pepkon
Founded Year 2022
Location France France
Employees 10
Industries Biotechnology
Funding Stage Non Equity Assistance
Business Model B2B, B2D
Revenue Model Licensing, Product Sales, Performance Based
Social

BounceWatch is an independent company data service, not affiliated with Pepkon. To contact Pepkon, visit pepkon.fr.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Pepkon compare?

A PDF of Pepkon and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Pepkon soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Pepkon

Pepkon, with its slogan "Pioneering breakthrough peptides for treating challenging cancers with precision and hope," is a French biotechnology startup established in 2022. The company’s primary focus is on developing first-in-class peptides aimed at treating cancers that are currently considered incurable or have a poor prognosis. Pepkon’s innovative drug candidates are backed by more than a decade of academic research, evidenced by seven scientific publications and two patent families.

Headquartered in France, Pepkon is part of the biotechnology industry, targeting a market with significant unmet needs. Notably, the company received a Non-Equity Assistance investment on 01 March 2023 from AGORANOV, showcasing early interest and support from prominent players in the sector.

Pepkon stands out as a promising investment opportunity due to its unique approach and scientific grounding, offering a potential breakthrough in cancer treatment. Their focus on precision medicine aligns with global trends towards personalized healthcare solutions, positioning them to make a significant impact in the field.

Business keywords: cancer treatment, peptide therapeutics, precision medicine, first-in-class drug development, leukemia treatment, solid tumors treatment, orphan cancer therapies, pediatric cancer treatment, pharmaceutical research, clinical trials, Chronic Lymphocytic Leukemia (CLL), Thrombospondin-1 peptides, academic research collaboration, oncology innovation

Services & Products

Peptide synthesis and testing
Drug optimization
Clinical trial advancement
Academic research collaboration
In-vivo and preclinical studies

Target Customers

Pharmaceutical companies Biotech researchers Oncologists Healthcare institutions Cancer patients

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Non Equity Assistance Undisclosed 1
AGORANOV
AGORANOV
01 Mar 2023

Pepkon Alternatives & Competitors

View All Alternatives
Pepkon vs
Sapience Therapeutics, Inc.
Sapience Therapeutics, Inc. United States

Changing the Tide to Achieve the Unachievable

Series B
24 employees
Biotechnology, Health and Wellness
Pepkon vs
Exelixis
Exelixis United States

Exelixis works on discovering, developing, and commercializing therapies for the treatment of cancer

IPO
1566 employees
Biotechnology
Pepkon vs
Cybrexa Therapeutics
Cybrexa Therapeutics United States

Changing the paradigm for cancer treatment through the development of antigen-independent peptide dr...

Series B
11 employees
Biotechnology, Health and Wellness
View all alternatives

FAQ About Pepkon

Pioneering breakthrough peptides for treating challenging cancers with precision and hope.
Pepkon was founded in 2022.
Pepkon is headquartered in France.
Pepkon operates in Biotechnology. Its work centres on cancer treatment, peptide therapeutics, precision medicine and first-in-class drug development. Its customers include Pharmaceutical companies, Biotech researchers and Oncologists.
Pepkon has a B2B and B2D business model. Its revenue comes from Licensing, Product Sales and Performance Based.
Pepkon has approximately 10 employees.
Pepkon has completed 1 funding round. The latest funding stage is Non Equity Assistance.
Pepkon offers: Peptide synthesis and testing, Drug optimization, Clinical trial advancement, Academic research collaboration, In-vivo and preclinical studies.
Top alternatives and competitors to Pepkon include Sapience Therapeutics, Inc., Exelixis, Cybrexa Therapeutics, Avenzo Therapeutics, Prelude Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Pepkon and Sapience Therapeutics, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Pepkon, https://bouncewatch.com/company/pepkon, updated 23 November 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout